Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Coherent Inc is a scientific & technical instruments business based in the US. Coherent shares (COHR) are listed on the NASDAQ and all prices are listed in US Dollars. Coherent employs 4,875 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$255.98|
|52-week range||$107.90 - $270.99|
|50-day moving average||$249.01|
|200-day moving average||$256.59|
|Wall St. target price||$256.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.94|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||2.05%|
|1 month (2021-08-26)||2.19%|
|3 months (2021-06-25)||-3.00%|
|6 months (2021-03-26)||-1.76%|
|1 year (2020-09-25)||137.79%|
|2 years (2019-09-26)||69.29%|
|3 years (2018-09-26)||46.92%|
|5 years (2016-09-26)||131.05%|
Valuing Coherent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Coherent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.34. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Coherent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Coherent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $166 million.
The EBITDA is a measure of a Coherent's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.4 billion|
|Operating margin TTM||7.9%|
|Gross profit TTM||$410.9 million|
|Return on assets TTM||3.84%|
|Return on equity TTM||-13.86%|
|Market capitalisation||$6.3 billion|
TTM: trailing 12 months
There are currently 2.2 million Coherent shares held short by investors – that's known as Coherent's "short interest". This figure is 0.1% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Coherent shares can be evaluated.
Coherent's "short interest ratio" (SIR) is the quantity of Coherent shares currently shorted divided by the average quantity of Coherent shares traded daily (recently around 195724.44836717). Coherent's SIR currently stands at 11.33. In other words for every 100,000 Coherent shares traded daily on the market, roughly 11330 shares are currently held short.
However Coherent's short interest can also be evaluated against the total number of Coherent shares, or, against the total number of tradable Coherent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Coherent's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Coherent shares in existence, roughly 90 shares are currently held short) or 0.0976% of the tradable shares (for every 100,000 tradable Coherent shares, roughly 98 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Coherent.
Find out more about how you can short Coherent stock.
We're not expecting Coherent to pay a dividend over the next 12 months.
Coherent's shares were split on a 2:1 basis on 1 March 1998. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Coherent shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Coherent shares which in turn could have impacted Coherent's share price.
Over the last 12 months, Coherent's shares have ranged in value from as little as $107.9 up to $270.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherent's is 1.5922. This would suggest that Coherent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Coherent, Inc. provides lasers, laser-based technologies, and laser-based system solutions for a range of scientific, commercial, and industrial research applications. It operates in two segments, OEM Laser Sources and Industrial Lasers & Systems. The company designs, manufactures, markets, and services lasers, laser tools, precision optics, and related accessories; and laser measurement and control products. Its products are used for applications in microelectronics, materials processing, original equipment manufacturer components and instrumentation, and scientific research and government programs. The company markets its products through a direct sales force in the United States, as well as through direct sales personnel and independent representatives internationally. Coherent, Inc.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.